Related Experiment Video
Updated: Jan 25, 2026
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Emerging drugs for essential thrombocythemia
Lucia Masarova1, Srdan Verstovsek1
1a MD Anderson Cancer Center , The University of Texas , Houston , TX , USA.
Insights
Essential thrombocythemia (ET) management remains focused on preventing complications, with limited changes in decades. Novel targeted and immunomodulatory agents are emerging, offering new therapeutic avenues for ET patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increased platelet count.
- Current ET management primarily aims to reduce thrombotic and hemorrhagic risks, with limited disease-modifying therapies.
- Despite advances in understanding ET pathogenesis, therapeutic options have seen minimal evolution over recent decades.
Purpose of the Study:
- To review current therapeutic strategies for essential thrombocythemia.
- To discuss novel agents and emerging treatment options for ET management.
- To provide an expert opinion on the challenges and future directions in ET drug development.
Main Methods:
- Comprehensive literature review of current and investigational therapies for essential thrombocythemia.
- Analysis of drug classes including JAK1/2 inhibitors, interferon-α, histone deacetylase inhibitors, telomerase inhibitors, and human double minute 2 inhibitors.
- Evaluation of agents in various stages of clinical development for ET.
Main Results:
- The treatment landscape for ET is expanding with several novel agents under investigation.
- Targeted and immunomodulatory agents represent promising new therapeutic classes for ET.
- While many agents are in development, only a subset is actively being evaluated in clinical trials.
Conclusions:
- Drug development for ET faces challenges due to the disease's prolonged and relatively benign course.
- Current therapies focus on complication prevention and symptom management, with no definitive disease-altering treatments available.
- Novel agents hold promise for expanding the ET treatment armamentarium, but their precise roles require further determination.
Abstract:
Introduction: Despite our recent progress in the understanding of essential thrombocythemia (ET) pathogenesis, the therapeutic management of this disease has remained largely unchanged in the past decades. Treatment has mostly focused on decreasing the risk of complications, especially prevention of thrombotic or hemorrhagic events. Areas covered: Over recent years, the treatment options of ET have been expanding with some novel agents on the horizon. The classes of agents described in this review include targeted and immunomodulatory agents, such as JAK1/2 inhibitors, interferon-α, histone deacetylase inhibitors, telomerase inhibitors and human double minute 2 inhibitors. These compounds entered various stages of development, albeit the only portion of them is currently actively undergoing evaluation in clinical trials. In this review, we look at the current therapies and discuss novel agents available in the management of ET. Expert opinion: The drug development in ET possesses several challenges stemming from its relatively benign and prolonged disease course. Therapy focused on reducing the risk of thrombotic and hemorrhagic complications and symptom management needs to be chosen wisely as a vast majority of these patients have a near-normal life expectancy. To date, no therapy has shown effective and definitive alteration of the disease behavior. Although novel agents are in development and hopefully some of them will extend treatment armamentarium of ET, their exact role remains to be determined.
Related Concept Videos
01:27Emerging Adulthood
01:25Compounds Essential to Human Function
Inorganic Compounds Essential to Human Functioning
Inorganic compounds essential to human functioning include water, salts, acids, and bases. These compounds are inorganic, i.e., they do not have a carbon-hydrogen bond. Water...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
01:30Introduction Cardiac Emergencies
01:29Applications of GIS: Disaster Management and Emergency Response
01:25Pharmacokinetics: Drug–Drug Interactions